MediciNov’s MN-166 Reduces Odds Of Heavy Drinking by 45% After 14 Days Of Treatment
MediciNov Inc (NASDAQ:MNOV) has announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use…
MediciNova Announces Positive Results from Phase 2 Trial of MN-166 in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 29 companies hit new 52-week lows.
The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira’s CEO Placed On Temporary Leave, 5 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)